Bixiye
P43-22 Updated Laboratory Services: General Guide Reimbursement Policy
Taariikhda barnaamijka Dhaqangalayso Agosto 01, 2022
Natiijooyinka Raadinta
Soo bandhiga 1701 - 1710 ee natiijooyinka 3688
Bixiye
QP67-22 MHCP Pharmacy Benefit Exclusion for Amvuttra™, Pemetrexed, and Skyrizi®
Taariikhda barnaamijka Dhaqangalayso Agosto 10, 2022
Bixiye
QP68-22 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective October 1, 2022
Taariikhda barnaamijka Dhaqangalayso Agosto 10, 2022
Bixiye
QP65-22 Commercial Pharmacy Benefit Exclusion for Select Medications
Taariikhda barnaamijka Dhaqangalayso Agosto 10, 2022
Bixiye
QP66-22 Commercial Pharmacy Benefit Exclusion for Amvuttra™ and Skyrizi®
Taariikhda barnaamijka Dhaqangalayso Agosto 10, 2022
Bixiye
QP55-22 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective September 1, 2022
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP56-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Cibinqo™ (abrocitinib)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP57-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Pyrukynd® (mitapivat)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP58-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Recorlev® (levoketoconazole)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP59-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Tarpeyo™ (budesonide)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022